Pharmaxis takes full control of collaboration on LOXL2 inhibitors and expands scientific program
The program scope has been doubled to encompass two lead candidates.
Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 7 of 8
Archive
Proactive news snapshot: Ergomed , PCF Group, Synairgen …
A glance at some of the day's highlights from the Proactive Investors newswire
Imaginatik lifted by contract win with US investment management company
"We continue to believe that in order for an organisation to build and sustain a business-critical innovation ethos and competency, technology and consultancy need to be implemented in a joined-up way," said Imaginatik
SynairGen to target COPD with inhaled interferon beta treatment
"A COPD programme is now both highly attractive and economically viable"
Archive
It's back to the future for the "Bombed Out" portfolio as NCC returns - again
As one might expect, we'd be better off buying and holding NCC and Rosslyn rather than buying, selling and then buying them back
Archive
Bombed Out portfolio likes the sound of Sound Energy
After a longish break working on the Proactive US site (and then working on his tan), John Harrington is back with a fresh batch of momentum stocks
Archive
Small caps movers: Stagnant UK economy starting to take its toll on some juniors
A look back at some of the more interesting stories on the junior market this week...
Archive
Proactive news snapshot: Synairgen, Silence Therapeutics, LoopUp Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Lots of potential for Synairgen in fibrosis, suggests broker finncap
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
Cyber security firm Shearwater soars as chairman increases holding
Sports Direct, Barratt Developments, Ryanair and EasyJet were among Wednesday's early market movers.
Synairgen reports strong interest in new fibrosis treatment ahead of Phase I trial
PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.
Archive
Proactive news round-up: Nasstar, Redx Pharma, Keywords Studios...
A glance at some of the stories on the Proactive newswire...
BP ticks higher as shareholders back CEO's reduced pay at AGM
A look at some of the biggest London-listed risers and fallers today
Synairgen pleased with the progress made with the LOXL2 programme
The company is pleased with the progress made with the LOXL2 programme and clearly is not giving up on its IFN-beta candidate
FTSE 100 closes lower as Trump fears grow; Dow Jones crashes
The UK blue chip index closed down 18.56 points at 7,503
Archive
Small cap movers: PhotonStar shines out on internet-of-things platforms roll-out to student accomodation
A look back at some of the week's more interesting stories from those on the junior market
Herencia Resources and Afarak gain, shares in Turbo Power Systems head south
Herencia Resources is a high riser among London's small caps today as it prepares a drill plan to enhance its copper projects
Synairgen believes interferon beta candidate has potential
The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.
Advanced Oncotherapy rallies on funding update
Some of the largest rises and falls in London at 10.00am: SynairGen, BOS Global, Angus Energy
Synairgen eyes lung fibrosis trial after encouraging lab results
IPF causes a build-up of scar tissue, which damages the structure of the lung and affects normal uptake of oxygen into the blood.